Because of the similar survival in the control arms of these studies (Table 1), and the higher overall survival in EORTC 22863, starting LHRH agonist on the first day of radiation for patients with high-risk prostate cancer should be the standard of care, until a better standard evolves. The gene discussed is GNRH1; the disease is prostate cancer.